Nevertheless, there were 65 deaths in the placebo group and 90 deaths in the lower-dosage lasofoxifene group . A trend toward more deaths due to cancer in the lower-dosage lasofoxifene group was close to however, not significant ; the utmost amount of fatal cancers at individual anatomical sites in the lasofoxifene organizations versus the placebo group was three. In the higher-dosage lasofoxifene group, there were 73 deaths from all causes and 25 deaths due to cancer ; neither price was significantly different from that in the placebo group . There have been 15 cases of main lung tumor in the lower-dose lasofoxifene group , 13 cases in the higher-dosage lasofoxifene group , and 4 instances in the placebo group . There have been no significant differences between the groups in the rate of all serious adverse events .The partnership between objective survival and response had been analyzed using time-dependent covariate and landmark methods, which are two well accepted statistical methods for analyzing the association between tumor objective response and survival. 109 patients were evaluated for efficacy and safety, including 69 patients who had no proof response to the newest prior therapy. These sufferers achieved a standard response rate of 29 percent predicated on independent central review of response, and 39 percent predicated on investigator review of response. Responses were durable with a median period of response of 10.1 months based on independent central review.